SCHEMBL5517154

SCHEMBL5517154

CCc1c(C(N)=O)cccc1-c1ccccc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.51
CTSD P07339 1/20 0.46
LMNA P02545 4/20 0.44
MAPT P10636 2/20 0.44
HPGD P15428 2/20 0.44
ALDH1A1 P00352 1/20 0.44
MEN1 O00255 1/20 0.44
NR1I2 O75469 1/20 0.44
CHRM2 P08172 1/20 0.44
CYP3A4 P08684 1/20 0.44
ADRA2A P08913 1/20 0.44
OPRK1 P41145 1/20 0.44
HTR2B P41595 1/20 0.44
SLC6A3 Q01959 1/20 0.44
KMT2A Q03164 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
CDC7 O00311 1/20 0.43
HTT P42858 3/20 0.43
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1135994 0.86 CTSD (0.49) PARP1CTSDLMNAMAPTMEN1
SCHEMBL16672550 0.85 MAPT (0.48) CTSDLMNAMAPTHPGDALDH1A1
SCHEMBL8086081 0.83 LMNA (0.60) LMNAMAPTALDH1A1MEN1NR1I2
SCHEMBL16673042 0.83 TSHR (0.54) LMNAMAPTALDH1A1MEN1CYP3A4
SCHEMBL527995 0.82 PARP1 (0.56) PARP1CTSDLMNAHPGDALDH1A1
SCHEMBL4434798 0.81 BCAT2 (0.44) PARP1LMNAMAPTHPGDALDH1A1
SCHEMBL5517143 0.81 PARP1 (0.50) PARP1CTSDLMNAMAPTHPGD
SCHEMBL14667558 0.81 HTR7 (0.49) HPGDALDH1A1HTR2BSMN1; SMN2HSD17B10
SCHEMBL4062441 0.80 PARP1 (0.54) PARP1CTSDMAPTHPGDALDH1A1
SCHEMBL4117324 0.80 PARP1 (0.54) PARP1CTSDLMNAHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208488-B2 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2007-04-24 US disclosed
US-6995269-B2 Guanidinobenzamides CHIRON CORPORATION (US) 2006-02-07 US disclosed
US-20050165003-A1 Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling ELAN PHARMACEUTICALS, INC. 2005-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165003-A1 Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling BACE1, PSEN1, BACE2 PARP1 3209/4885CTSD 1200/4885LMNA 2773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.